Education
About Us
Working with TipRanks
Follow Us
Curevac N.V. (DE:5CV)
:5CV
5CV Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.00 - €4.81
Previous CloseN/A
Volume42.95K
Average Volume (3M)118.11K
Market Cap
€529.94M
Enterprise Value€92.14M
Total Cash (Recent Filing)-€60.63M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)4.9
Beta0.47
Next Earnings
Apr 10, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding224,305,680
10 Day Avg. Volume153,377
30 Day Avg. Volume118,114
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.44Price Target Upside254.53% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
CureVac News
PremiumCompany Announcements
CureVac Receives FDA Clearance for Phase 1 Trial of mRNA Immunotherapy
PremiumCompany Announcements
CureVac Wins Patent Ruling Against BioNTech
---
Bulls Say, Bears Say
Bulls Say
Financial OutlookCureVac ended with €550.9M in cash following GSK's payment of €400M for the revised COVID/flu agreement.
Patent RulingThe European Patent Office largely dismissed the patent opposition filed by BNTX challenging the validity of Curevac's foundational patent for split poly-A tail technology and confirmed its validity, subject to amendment.
Revenue PerformanceRevenue significantly surpassed expectations, driven by a new GSK license agreement and contributions from other collaborations.
Bears Say
Legal ChallengesNear-term focus remains on an intellectual property dispute with PFE/BNTX, indicating ongoing legal challenges.
Patient OutcomesMost patients progressed following the main treatment period.
Workforce ReductionA 30% workforce reduction is expected to complete by the end of the year as part of the company's restructuring efforts.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
0.06%
Mutual Funds
0.35% Other Institutional Investors
98.46% Public Companies and
Individual Investors
5CV FAQ
What was Curevac N.V.’s price range in the past 12 months?
Curevac N.V. lowest stock price was €2.00 and its highest was €4.81 in the past 12 months.
What is Curevac N.V.’s market cap?
Curevac N.V.’s market cap is €529.94M.
When is Curevac N.V.’s upcoming earnings report date?
Curevac N.V.’s upcoming earnings report date is Apr 10, 2025 which is in 2 days.
How were Curevac N.V.’s earnings last quarter?
Curevac N.V. released its earnings results on Nov 12, 2024. The company reported €1.51 earnings per share for the quarter, beating the consensus estimate of €1.41 by €0.1.
Is Curevac N.V. overvalued?
According to Wall Street analysts Curevac N.V.’s price is currently Undervalued.
Does Curevac N.V. pay dividends?
Curevac N.V. does not currently pay dividends.
What is Curevac N.V.’s EPS estimate?
Curevac N.V.’s EPS estimate is -0.21.
How many shares outstanding does Curevac N.V. have?
Curevac N.V. has 224,305,680 shares outstanding.
What happened to Curevac N.V.’s price movement after its last earnings report?
Curevac N.V. reported an EPS of €1.51 in its last earnings report, beating expectations of €1.41. Following the earnings report the stock price went down -0.685%.
Which hedge fund is a major shareholder of Curevac N.V.?
Currently, no hedge funds are holding shares in DE:5CV
---
CureVac Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€8.44 (254.53% Upside)
€8.44 (254.53% Upside)
Blogger Sentiment
Neutral
DE:5CV Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $579.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.39%
12-Months-Change
Fundamentals
Return on Equity
17.08%
Trailing 12-Months
Asset Growth
6.87%
Trailing 12-Months
Company Description
Curevac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
---
5CV Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive trajectory for CureVac, with significant licensing deals, promising pipeline developments, and strategic cost reductions. However, ongoing litigation and certain financial impairments present challenges.Read More>---
5CV Stock 12 Month Forecast
Average Price Target
€8.44
▲(254.53% Upside)
Technical Analysis
Best Analysts Covering 5CV
1 Year
1 Year Success Rate
1/26 ratings generated profit
1 Year Average Return
-37.40%
reiterated a buy rating 2 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 3.85% of your transactions generating a profit, with an average return of -37.40% per trade.
---